Background
Urologic cancer is a group of cancers that occur in the urinary system. The incidence of urologic cancer is still high. Kidney cancer is the seventh most common malignancy in men and the ninth most common malignancy in women globally [
1]. Bladder cancer is the fourth and eleventh most common cancer among men and women worldwide [
2]. Prostate cancer is the most common type of cancer in men and the second leading cause of cancer-related death in men [
2]. Despite advances in the early diagnosis and treatment of urologic cancers, the prognosis remains poor due to local recurrence or distal metastasis [
3,
4]. Therefore, noninvasive detection tools such as serum biomarkers are increasingly valued for their simplicity and predictive value.
Inflammation is an important predictor of tumor invasion, progression and metastasis [
5]. Therefore, a series of biological indicators based on inflammation and/or nutritional status, such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), have been reported as efficient tumor biomarkers [
6‐
8]. The systemic immune-inflammation index (SII), as a relatively new inflammatory index based on peripheral lymphocyte, neutrophil, and platelet counts, was evaluated to have high diagnostic value for the prognosis of cancer [
9,
10]. Poor outcomes have been recently reported in patients with high SII values based on studies of other cancers, such as respiratory system cancers and digestive system cancers [
7,
8,
11]. There is still a debate for the use of SII in urologic cancers, although an increasing number of studies has been performed on this topic, and the sample size in the existing research is not that large [
12,
13]. Therefore, we conducted a meta-analysis to investigate the prognostic role of SII in patients with urologic cancers.
Methods
Search strategy
To identify relevant available articles irrespective of language, the electronic databases of EMBASE, PubMed and the Cochrane Library were rigorously searched from inception to April 2020. The search terms included ‘urinary cancer’, ‘bladder cancer’, ‘kidney cancer’, ‘prostate cancer’ and ‘systemic immune-inflammation index’ or ‘SII’. Both MeSH terms and entry terms were utilized in the literature search. In addition, we screened all the references of the relevant studies and reviews to attain additional eligible studies.
Inclusion and exclusion criteria
The studies included in the meta-analysis met the following inclusion criteria: (1) adult patients who were diagnosed with urinary cancer; (2) SII, which was defined as the multiplication of the neutrophil and platelet counts divided by the lymphocyte count, was available or could be calculated, and SII was presented as a binary variable with a selected cut-off value; (3) the primary outcome was overall survival (OS), and the relationship between OS and SII was analyzed; (4) the hazard ratios (HRs) with the 95% confidence intervals (95% CIs) were available or could be calculated; and (5) the study quality was assessed in accordance with the Newcastle–Ottawa quality assessment scale, and the included studies had a score of no less than 6.14 The exclusion criteria were as follows: (1) studies on the children or pregnant women; (2) experimental studies on the cell lines or animals; (3) the use of anti-inflammatory or immune-suppressive drugs in the studies; and (4) publication types including case reports, editorials, meta-analyses and reviews. When duplicated studies from the same population were included, the latest and most complete study was included.
The following information was extracted from the selected studies: first author, publication year with the country or region of the study, study type, kind of cancer, number of samples, age of patients, follow-up time, cut-off value of SII and how the cut-off was selected, treatment that the patients received, stage of the cancer and data on the primary and secondary outcomes. Analysis results from univariate and multivariate analyses were extracted. Effect values in multivariate analysis were preferred, and subgroup analysis according to the different analysis methods was performed. If the HRs with the 95% CI were not available, they were calculated from survival curves using Engauge Digitizer. Two researchers extracted the information independently, and any disagreements were resolved by a third individual.
Statistical analysis
The meta-analysis was performed using RevMan software (version 5.3; The Nordic Cochrane Center, Cochrane Collaboration, Copenhagen, Denmark). The HRs and 95% CIs from the survival analyses of the included studies were pooled to assess the prognostic role of SII in urinary cancer patients, and the odds ratios (ORs) with the corresponding CIs were pooled in the analysis of binary variables. The heterogeneity of the results across studies was qualitatively tested using Cochran’s Q-test and quantified using I2 statistics. I2 statistics of 25%, 50% and 75% represent the low, moderate and high levels of heterogeneity, respectively. A fixed-effects model was used when there was low heterogeneity; otherwise, a random-effects model was used. Publication bias was evaluated by funnel plots. Sensitivity analysis was performed by omitting individual studies one by one to assess the reliability of the results. A P value less than 0.05 was considered statistically significant.
Discussion
To our knowledge, this is the first meta-analysis that analyzed the prognostic value of SII in urologic cancers. A total of 14 published articles or conferences with 3074 cases were included in this study. From the pooled results, we found that UC patients with a high SII value had a worse prognosis for OS (HR 2.58, 95% CI 1.59–4.21). Moreover, we performed subgroup analysis to assess the prognostic significance of SII. The subgroup analysis results showed that high SII was a prognostic marker for worse OS in PC (prostate cancer) and UC (urothelial carcinoma). Similarly, high SII was also negatively correlated with PFS, CSS, and ORR. Considering the above results, SII could serve as a prognostic factor for urinary cancers.
Currently, an increasing number of biological markers have been applied in clinical work due to their inexpensiveness and ready availability. The lymphocyte count, plasma fibrinogen, NLR, PLR and LMR have been proven to be valuable for the prognosis of cancer patients. However, when only one or two parameters were involved, these predictors became unstable and tended to be susceptible to the influence of other confounding factors [
25]. SII, defined as P (platelet count) x N (neutrophil count)/L (lymphocyte count), combines NLR with platelet count and might have a better predictive power than NLR [
26]. As a more objective tumor marker, SII reflects the balance between host inflammation and the state of the immune response [
27].
SII has been reported in other studies as a predictor for cancer outcomes, such as small cell lung cancer, GI (gastrointestinal) cancer, and hepatocellular carcinoma [
7,
8,
25]. The prognostic role of SII in tumors can be explained by the following mechanisms. Numerous studies have reported the relationship between inflammation and cancer and found that cancer-related inflammation is an indispensable component of the tumor microenvironment [
28,
29]. Circulating inflammatory cells, such as neutrophils, lymphocytes, and platelets, play important roles in the development and progression of tumors [
5,
33]. Patients with cancer often suffer from a hypercoagulable state, and platelets can mediate the survival and growth of tumor cells by regulating the formation of micrometastases [
30]. Lymphocytes inhibit the proliferation and growth of tumor cells by cytotoxic cell death in cancer immune surveillance and resistance [
31,
32]. In addition, neutrophils play an important role in metastasis and progression [
5,
33]. Thus, SII could explain why higher levels of neutrophils and platelets and lower levels of lymphocytes indicate a weak immune response but a strong inflammatory response.
The limitations of this study include the following aspects. First, most of the articles included in this study were retrospective studies, and only one was a prospective study. Second, the number of studies that met the requirements was not that large, and the sample size included was relatively small, especially in the subgroup analysis. Third, the cut-off values of SII varied in different studies, and the calculation methods were inconsistent. A few studies did not provide multivariate analysis results, so we used univariate results instead. Finally, despite the subgroup analysis and the sensitivity analysis being performed, we were not able to confirm whether different types of tumors and different treatments would lead to bias in the results.
In conclusion, the outcomes presented in this meta-analysis indicated that high SII was independently related to poor prognosis in patients with urologic cancers. SII could be a significant and cost-effective prognostic indicator for urinary cancers. Of course, well-designed, large-scale multicenter studies are needed to validate the clinical value of SII as a prognostic biomarker for urologic cancers.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.